Nanobiotix (NBTX) Cash & Equivalents (2018 - 2025)

Nanobiotix's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $61.4 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 15.53% year-over-year to $61.4 million in Q4 2025; TTM through Dec 2025 was $61.4 million, a 15.53% increase from a year earlier, with the FY2025 full-year figure at $59.6 million, up 12.13% from the prior year.
• Cash & Equivalents rose to $61.4 million in Q4 2025 per NBTX's latest filing, from $32.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $123.2 million in Q2 2021 and bottomed at $23.6 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $64.3 million (2022), against an average of $65.2 million.
• Across the five-year window, Cash & Equivalents plunged 64.98% in 2023 and soared 203.3% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $96.0 million in 2021, then tumbled by 56.02% to $42.2 million in 2022, then surged by 91.82% to $81.0 million in 2023, then slumped by 34.38% to $53.1 million in 2024, then grew by 15.53% to $61.4 million in 2025.
• Per Business Quant, the three latest NBTX Cash & Equivalents figures stand at $61.4 million (Q4 2025), $32.6 million (Q2 2025), and $53.1 million (Q4 2024).